Abstract: A significant interest lies in compositions that hinder the metastatic process. This process, along with recurrence, is associated with a subset of highly invasive tumorigenic cells expressing CD44. Described herein are CD44-modulating peptide compositions for combination therapy as well as method of use thereof to treat or ameliorate tumors or cancers like ovarian cancer, endometrial cancer, or triple-negative breast cancer.

Abstract: Methods and CD44-modulating peptide compositions for treating or ameliorating ascites, for treating or ameliorating a tumor or cancer, wherein the compositions feature binding moieties such as monoclonal antibodies or fragments thereof specific for CD44 that inhibit CD44 activity, or CD44-modulating peptides that bind to and modulate activity of CD44, optionally featuring a pharmaceutically acceptable carrier. The binding moieties herein may be used with a secondary therapy. In some embodiments, the monoclonal antibody or fragment thereof binds to at least a portion of the cryptic region of CD44.

Abstract: The present invention relates to methods of treatment for cancer using SPL-108 polypeptide (also known as A6 peptide or A6, a CD44 modulating peptide; FIG. 1; SEQ ID NO:1) based on the TP53 status of the cancer. In particular, this invention relates to such methods of treatment by using TP53 mutational status to guide the administration of an SPL-108 polypeptide or a variant thereof alone or in combination with a standard-of-care treatment for patients with cancer. TP53 mutational status is used to select patients that may or may not respond to SPL-108 polypeptide or a variant thereof; specific mutations TP53 predict the response of patients including progressive disease, stable disease, and/or partial/complete response to SPL-108. Such methods of the present invention are used to treat cancer to alleviate and/or prevent symptoms of cancer, and/or to avoid side effects commonly associated with treating cancer.

Abstract: This invention relates to methods of treatment for arthritis using SPL-108 polypeptide. In particular, this invention relates to such methods of treatment by the administration of an SPL-108 polypeptide (also known as A6 peptide, a CD44 modulating peptide) or a variant thereof alone or in combination with a standard-of-care treatment for arthritis to alleviate and/or prevent symptoms of arthritis and/or to avoid side effects commonly associated with treating arthritis. Such methods of the present invention are used to treat inflammatory conditions such as rheumatoid arthritis, osteoarthritis, reactive arthritis, and/or psoriatic arthritis.

Abstract: The present invention relates to methods for modulating efflux of drugs based on binding to a protein region of CD44 in part comprising the amino acid sequence specified in the provisional application referenced above, and incorporated in its entirety by reference herein (“PROV”). In some aspects, the present invention relates to methods for treatment of cancer by preventing the cellular efflux of therapeutic drugs; for example, preventing the cellular efflux of anti-cancer agents, for example a taxane, by contacting a CD44-modulating peptide, comprising the amino acid sequence specified in the provisional application referenced above, and incorporated in its entirety by reference herein (“PROV”).

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

Abstract: Provided herein are therapeutic combinations of A6 peptide (SEQ ID NO: 1) and more anti-cancer agents, radiation therapy, or a combination thereof and the use of such combinations in the treatment of cancer.

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

Abstract: A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an ?6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.

Abstract: A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an ?6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition variants. A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an ?6 polypeptide to bind to a CD44 polypeptide and modulate signal transduction activity for a sufficient period of time to treat the disease. Other methods include using the peptide of SEQ ID NO:3 or an ?6 polypeptide for diagnosing, identifying a subpopulation of subjects responsive to treatment, and screening for compounds that bind a CD44 polypeptide.

Abstract: A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an ?6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.

Abstract: A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an ?6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition variants. A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an ?6 polypeptide to bind to a CD44 polypeptide and modulate signal transduction activity for a sufficient period of time to treat the disease. Other methods include using the peptide of SEQ ID NO:3 or an ?6 polypeptide for diagnosing, identifying a subpopulation of subjects responsive to treatment, and screening for compounds that bind a CD44 polypeptide.

Abstract: The present invention includes a molecular melt composition comprising an antioxidant and a coupling agent. The molecular melt is partially amorphous in nature. The invention also includes a method for making the molecular melt composition and a method for using the molecular melt to produce coupled polymers. The invention further includes a method for using an antioxidant to phlagmatize a coupling agent.

Abstract: The present invention yields a coagent-mediated, grafted copolymer prepared from a free radical-mediated reaction of a mixture containing or made from (a) a first free-radical reactive organic polymer, (b) a second free-radical reactive organic polymer, and (c) a coagent selected from the group consisting of allyl, vinyl, and acrylate coagents, wherein the first and second organic polymers are chemically dissimilar polymers as determined by at least one physical property yet the organic polymers have similar reactivity in radical-mediated additions to the coagent.

Abstract: Disclosed are adhesives and processes for preparing the same, comprising at least one first homogeneous ethylene/?-olefin interpolymer, and optionally at least one tackifier, and optionally at least one plasticizer. The claimed adhesives are useful as adhesives such as are employed in various applications, such as in masking tape, clear office tape, labels, decals, bandages, decorative and protective sheets (such as shelf and drawer liners), floor tiles, sanitary napkin/incontinence device placement strips, sun control films, the joining of gaskets to automobile windows, packaging, bookbinding, construction of nonwoven articles, and insulation bonding.

Abstract: The present invention includes a molecular melt composition comprising an antioxidant and a coupling agent. The molecular melt is partially amorphous in nature. The invention also includes a method for making the molecular melt composition and a method for using the molecular melt to produce coupled polymers. The invention further includes a method for using an antioxidant to phlagmatize a coupling agent.